Mayo Score for Ulcerative Colitis
Mayo Score for Ulcerative Colitis Activity · Also known as: Mayo Clinic Score, UC Mayo Score
The Mayo Score is a validated tool for assessing disease activity in ulcerative colitis, integrating clinical symptoms and endoscopic findings. Introduced by Schroeder and colleagues in 1987, it has become the reference standard for UC activity assessment in clinical trials and practice. The score combines stool frequency, rectal bleeding, overall physician global assessment, and endoscopic subscore into a single 0–12 scale.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The Mayo Score is the gold standard for UC activity assessment in clinical trials, regulatory submissions (FDA, EMA), and comparative effectiveness research. In routine clinical practice, it is used at baseline (diagnosis confirmation, baseline severity), at treatment escalation decisions (if clinical worsening despite therapy), and at remission assessment (to verify mucosal healing before stepping down or discontinuing therapy). It is less practical for every office visit due to the requirement for endoscopy, but is essential at major decision points.
Strengths & limitations
- Gold standard validity: Adopted by FDA and EMA as primary endpoint in UC clinical trials; extensively validated in >500 RCTs.
- Dual assessment: Combines subjective symptoms and objective endoscopic findings, capturing the full spectrum of UC pathology.
- Mucosal healing target: Endoscopic subscore ≤1 provides a specific target for remission that correlates with long-term steroid-free remission.
- Simplicity and reproducibility: Four items with clear 0–3 anchors minimize scoring ambiguity and interrater variability among endoscopists.
- Requirement for endoscopy: The endoscopic component mandates sigmoidoscopy or colonoscopy, limiting use in routine office visits and restricting frequency of assessment.
- Interobserver variability in endoscopy: Scoring of mucosal inflammation depends on endoscopist training and standardization; substantial variation exists in categorizing mild friability.
- Temporal mismatch: Stool frequency and bleeding may improve within days, while endoscopic healing lags by weeks; a patient with symptomatically improved disease may have persistent endoscopic activity.
- Sampling bias: Sigmoidoscopy assesses only the rectosigmoid; pancolonic proximal disease may be missed, particularly in extensive colitis.
Frequently asked
Can the Mayo Score be calculated without endoscopy?
Partially. Stool frequency, rectal bleeding, and physician global assessment can be scored without endoscopy, yielding a subscale score of 0–9 (often called 'partial Mayo' or 'Clinical Mayo'). However, the full Mayo Score (0–12) requires the endoscopic subscore and is the standard for trials. In clinical practice, if endoscopy cannot be performed immediately, the partial Mayo is acceptable for interim monitoring.
What is the difference between the endoscopic subscore and the full Mayo Score?
The endoscopic subscore (0–3) is a single component of the full Mayo Score. It assesses rectal/sigmoid mucosal inflammation during endoscopy. The full Mayo Score includes endoscopic subscore plus stool frequency, bleeding, and physician assessment, totaling 0–12. For remission, both the full score (≤2) and endoscopic subscore (≤1) must be ≤1.
How often should Mayo Score be assessed?
At baseline (diagnosis) for severity stratification. Then at 4–6 weeks during induction therapy to assess early response. At 8–12 weeks post-induction, perform endoscopy and full Mayo to confirm mucosal healing before stepping down therapy. In remission, repeat every 6–12 months or if symptoms recur. Routine office visits without endoscopy can use partial Mayo for symptom monitoring.
Is a Mayo Score of 2 with endoscopic subscore of 2 considered remission?
No. The definition of remission is total Mayo ≤2 AND endoscopic subscore ≤1. If the endoscopic subscore is 2 (marked erythema and friability), the patient has persistent endoscopic inflammation and does not meet remission criteria, even if the total score is ≤2. This patient requires continued or escalated medical therapy.
Can stool frequency be counted if the patient is on loperamide or other antidiarrheal agents?
Yes, but with caution. Antidiarrheal agents may artificially lower stool frequency while masking ongoing inflammation. If a patient achieves low stool frequency solely due to antidiarrheals without addressing underlying inflammation, endoscopic disease may persist. Always verify with endoscopy and rectal bleeding history; do not rely on frequency alone if antidiarrheals are used.
Sources
- Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New England Journal of Medicine, 317(26), 1625–1629. DOI: 10.1056/NEJM198712243172603 ↗
How to cite this page
ScholarGate. (2026, June 3). Mayo Score for Ulcerative Colitis Activity. ScholarGate. https://scholargate.app/en/gastroenterology/mayo-score-uc
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Crohn's Disease Activity IndexGastroenterology↔ compare
- Harvey-Bradshaw IndexGastroenterology↔ compare
- Short Inflammatory Bowel Disease QuestionnaireGastroenterology↔ compare
- Simple Clinical Colitis Activity IndexGastroenterology↔ compare